Send to

Choose Destination
See comment in PubMed Commons below
Ther Adv Neurol Disord. 2009 Sep;2(5):291-7. doi: 10.1177/1756285609337992.

Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.

Author information

Neurovirology Research Laboratory, VASLCHCS and Department of Neurology, University of Utah, Salt Lake City, UT, USA.


We performed a retrospective review of side effects and clinical outcomes in relapsing-remitting (RR) multiple sclerosis (MS) patients receiving long-term treatment with daclizumab. Twelve patients with RR MS were initially treated with daclizumab at 1 mg/kg IV, again 14 days later and then monthly treatments (average duration 42.1 months). Daclizumab dose (0.85 mg/kg to 1.5 mg/kg) was adjusted based on clinical response. Daclizumab was generally well tolerated. There was a significant reduction in relapse rate and improvement in Expanded Disability Status Scores (EDSSs) (p < 0.0001). Long-term treatment with daclizumab in RR MS patients has apparent benefit that will require formal confirmation.


clinical outcomes; interleukin 2 receptor alpha; long-term daclizumab therapy; side effects

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center